Xenitra reports explosive Q3 growth with sales jumping 300% to $8.3 million, driven by its nutritionals business and strategic acquisitions. The company's acquisition of Hong Kong-based Fukang Trading establishes a fully operational over-the-counter medicines platform in Hong Kong and China, opening a new revenue channel with higher profit margins. A landmark $30 million partnership with Rockcheck Group for Danone products provides a solid revenue foundation for the coming year. March sales alone exceeded $4 million, bringing the business close to full recovery of 2024 financial year levels following restructuring. Management highlights two new high-margin sales channels in OTC medicines and blockchain tokenized sales expected to drive significant growth in Q4 and beyond.
Post from MarketNews_en
Log in to interact with content.